ArticleCancer medicine2020
Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Observational
- Prognostic impact of cancer-directed surgery in primary pulmonary lymphoma: a population-based, propensity score-matched analysis.Translational cancer research · 2026Article
- Assessing PET-CT versus conventional CT: a meta-analysis on diagnostic efficacy, prognosis, and post-surgical wound healing in lung mucosal marginal zone lymphoma.Frontiers in oncology · 2026Article
- Primary Pulmonary Marginal Zone Lymphoma Presenting With Asymptomatic Lung Consolidation.Case reports in pulmonology · 2026Article
- A unique case of extranodal marginal zone lymphoma with synchronous pulmonary and dermatologic manifestations.Respiratory medicine case reports · 2025Article
- [Research Progress of Pulmonary Extranodal Marginal Zone Lymphoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Long-Term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Study.Acta haematologica · 2024Article
- Radiological and pathological analysis of the galaxy sign in patients with pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma.Thoracic cancer · 2023Article
- Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.Expert review of hematology · 2023Review
- Management of marginal zone lymphomas.Hematology. American Society of Hematology. Education Program · 2022Article
- Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis.Cancer medicine · 2020Article
- MALToma with a 'B'-Not for Benign, but for Bronchus-Associated: A Rare Case of Bronchus-Associated Lymphoid Tissue Lymphoma.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Pulmonary marginal zone lymphoma (PMZL) is the most common non-Hodgkin lymphoma affecting the lung. PMZL is usually an indolent disease. Clinical and radiological variables associated with shorter survival are largely unknown and no consensus exists on preferred treatment strategy in PMZL. Herein we aimed to identify clinical and radiological features associated with shorter survival and inferior treatment outcomes. Forty patients with PMZL were analyzed. FDG-avid disease was evident in most patients (93%) with staging PET/CT (n = 15). With a median follow-up in treated patients (n = 38) of 8.4 years (range 0.07-18.44), the median progression-free survival (PFS) and overall survival (OS) were 7.5 years (95% CI 1.8-9.5) and 15.7 years (95% CI 9.3-NE) respectively. Shorter PFS was observed in patients who presented at diagnosis with elevated LDH, B symptoms, advanced stage and failed to achieve complete response (CR) after initial treatment. Patients with multifocal lung disease, extrapulmonary MZL and cavitary lesions on CT scans exhibited shorter PFS. Nevertheless, no clinical or radiologic findings were associated with shorter OS. All patients treated with surgery (n = 4) and radiation therapy (n = 3) achieved and remained in CR. No higher grade transformations occurred during the follow-up period. PMZL exhibited excellent outcomes with a 15-year PMZL-related OS of 94.9% (95% CI: 81.25%-98.7%). Radiation therapy and surgery are potentially curative strategies in localized PMZL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.